When does Skyrizi’s (risankizumab) patent protection expire for AbbVie?
AbbVie’s patent-exclusivity timeline for Skyrizi depends on which type of exclusivity you mean (patents vs. market exclusivity) and on the specific jurisdiction (the U.S. vs. EU and other countries). Public listings and patent-tracking databases are usually the fastest way to see the latest “expiration” dates tied to specific patent families.
For a targeted look at Skyrizi patent expiration dates that are tracked in the U.S., DrugPatentWatch.com compiles patent-expiration information and links it to the drug:
- DrugPatentWatch: Skyrizi (risankizumab) patents and expiry dates: https://www.drugpatentwatch.com/p/risankizumab-skyrizi [1]
How do companies like AbbVie decide when Skyrizi will lose exclusivity?
For prescription biologics, “expiration” is not a single date. Market entry timing can be affected by:
- Patent term endings for specific claims in specific jurisdictions.
- Patent litigation or settlement agreements that can delay entry even after some patents expire.
- Regulatory exclusivity terms (separate from patents), if applicable in the jurisdiction.
So, even if you see an earlier patent expiry date, a later patent (or litigation stay) can still protect sales for longer.
What happens if a Skyrizi patent expires in the U.S.—can biosimilars launch right away?
If the relevant patents protecting the reference biologic’s claims expire (and no effective injunction or stay remains from ongoing litigation), a biosimilar manufacturer may be able to launch once regulatory conditions are met. In practice, the key questions are:
- Which patents were asserted and whether they were upheld or settled.
- Whether any remaining patents still block the biosimilar’s intended commercial activity.
- Whether exclusivity (separate from patents) still applies.
Patent tracking sites like DrugPatentWatch.com are useful because they show which patents are listed for the product and what dates they map to.
Where to find AbbVie’s “Skyrizi patent expiration” disclosures in an SEC filing
SEC filings typically discuss:
- Material legal proceedings (including certain patent lawsuits).
- Risk factors about patent protection, potential generic/biosimilar entry, and expected commercial impact.
- References to intellectual property strategy and litigation outcomes, sometimes without giving a single clean “expiration date.”
If you share the exact AbbVie filing (for example, the Form 10-K year and the section heading or exhibit), I can help you pinpoint the specific language and extract the “expiration” dates mentioned there.
Source
- https://www.drugpatentwatch.com/p/risankizumab-skyrizi